Publikationen 2025
97. Phase 3 Study of ivosidenib (IVO) and azacitidine (AZA) with or without venetoclax in adult patients withnewly diagnosed IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy (EVOLVE-1). Dohner H, Huls GA, Vyas P
Blood. 2025; 146 Suppl 1(): 5192-5192.
96. Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across DiseaseStates. Lachowiez CA, Asimomitis G, Bernard E, Devlin SM, Tazi Y, Creignou M, Germing U, Gattermann N,Gilkes A, Thomas I, Bullinger L, Döhner K, Malcovati L, Othman J, Dillon R, Eisfeld AK, Nicolet D, IssaGC, Daver N, Kadia TM, DiNardo CD, Ravandi F, Garcia-Manero G, Montalban-Bravo G, Russell N,Cazzola M, Döhner H, Huntly BJP, Hasserjian RP, Hellström-Lindberg
Blood Cancer Discov. 2025; 6(5): 425-436.
95. Characterising HIV-Indicator conditions among two nationwide long-term cohorts of people living withHIV in Germany (1999-2023). Krings A, Kollan C, Schmidt D, Gunsenheimer-Bartmeyer B, Valbert F, Neumann A, Wasem J, BehrensGMN, Bickel M, Boesecke C, Esser S, Dröge P, Ruhnke T, Koppe U, Grüner B as Collaborator HIV-1 Seroconverter, ClinSurv-HIVstudy groups
Infection. 2025; 53(3): 1013-1028.
94. Complicated ulceroglandular tularemia. Trautmann D, Naka T, Gruener B
Infection. 2025 Dec 10. doi: 10.1007/s15010-025-02691-w. Online ahead of print.
93. Disseminated fusariosis after allogenic hematopoietic stem cell transplantation: case report. Gantner A, Hagemann JB, Grüner B, Walther G, Neagoie A, Wais V, Döhner H, Sala E
Infection 2025; 53(2): 727-731.
92. Semi-quantitative software evaluation of COVID-19 CT examinations-correlation with clinical parameters. Trif N, Kloth C, Büttner SM, Egenrieder N, Wolf D, Schmidt SA, Vogele D, Sollmann N, Flack F, PetersL, Grüner B, Jungwirth B, Stenger S, Stamminger T, Beer M
J Thorac Dis. 2025; 17(10): 7571-7584.
91. Leishmaniasis in Syria - A call for action of the European Society for Clinical Microbiology and InfectiousDiseases (ESCMID) Study Groups for Infections in Travellers and Migrants (ESGITM) and for Clinical Parasitology (ESGCP).
Abbara A, González-Sanz M, AlKharrat A, Khalife M, Elferruh Y, Almhawish N, Abbara S, Marroush S,Shortall C, Ahmed SH, Alhazmi A, Alvarez-Martinez MJ, Asaduzzaman M, Al Balushi A, Barboza AP,Brekke H, Di Carlo P, Cascio A, Chiodini P, Colpani A, Díaz-Menéndez M, Elkheir N, Farkas FB, Garg P, Grüner B, Guimarães AR, Holmberg V, Ioannou P, Jordão S, Kim JA, Lakatos B, Leblebicioglu H,Llenas-García J, Losada-Galván I, Martinez GE, Monk EJM, Nedu E, Nwofe JO, O'Regan R, Paggi R,Pinho JH, Pontali E, Priyadarshi M, Rath B, Rathish B, Rezzonico LF, Rizk N, Ronnberg C, Morante-RuizM, Salvati A, Scarso S, Sempere-Alcocer MA, Sepulcri C, Costescu Strachinaru DI, Tamarozzi F,Tavares R, Ursini T, Verweij JJ, Wejse CM, Rodriguez-Morales AJ, ESGITM and ESGCP
Travel Med Infect Dis. 2025; 66():102849. Epub 2025 Apr 2.
90. Clinical, Diagnostical, and Epidemiological Findings at First Diagnosis of Alveolar Echinococcosis: ASingle-Center Cohort Study. Allgäuer AL, Peters L, Grunenberg A, Jiang W, Trautmann D, Westerwinter C, Grüner B
Visc Med. 2025; 41(6): 310-319.
89. Minimally Invasive Surgical Strategies for Alveolar Echinococcosis of the Liver. Steinkraus KC, Birgin E, Zaimi M, Grüner B, Rahbari N, Kornmann M
Visc Med. 2025 Apr 3: 1-8.
88. Updating Clinical Management of Cystic and Alveolar Echinococcosis: Insights and Challenges.Gruener B, Kornmann M
Visc Med. 2025; 41(6): 307-309.
87. Erratum to: "Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance". Schmidt C, Scheubeck G, Jurinovic V, Sökler M, Forstpointner R, Buske C, Viardot A, Keller U, Graeven U, Marks R, Hänel M, Liersch R, Dürig J, Pott C, Hoster E, Unterhalt M, Hiddemann W.
Haematologica. 2025 Dec 1;110(12):3180-3181.
86. ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed IDH1 mutant acute myeloid leukemia. Vyas P, Salek S, Vives S, Recher C, Döhner H, Venditti A, Derrien H, Chatin S, De La Bigne AM, Pelouchova J, Hills R, Nier S.
Future Oncol. 2025 Dec;21(29):3721-3729. Epub 2025 Nov 15.
85. Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML. Nier S, Pelouchova J, Hills R, Salek S, Derrien H, Chatin S, De La Bigne AM, Vives S, Recher C, Döhner H, Venditti A, Vyas P.
Future Oncol. 2025 Dec;21(29):3713-3719. Epub 2025 Nov 19.
84. Functional and molecular analyses reveal impaired HSPCs in Multiple Myeloma patients post-induction.Baumhardt TM, Amoah A, Hoenicka M, Liebold A, Sakk V, Soller K, Vollmer A, Kull M, Kronke J, Mallm JP, Geiger H, Mulaw M. Stem Cells Transl Med. 2025 Nov 14;14(11):szaf061. doi: 10.1093/stcltm/szaf061.
83. Lymphotoxin alpha eradicates acute myeloid leukemia and simultaneously promotes healthy hematopoiesis in mice. Höckendorf U, Dutta S, Kloos A, Runtsch M, Zötsch C, Vosberg S, Wang Y, Kienreich S, Flasch B, Malovan G, Jäger V, Stanzer S, Prein S, Odinius TO, Wagner CV, Buschhorn L, Dill V, Perfler B, Haferlach T, Döhner K, Götze KS, Ruland J, Bassermann F, Wahida A, Heikenwälder M, Branca C, Schmöllerl J, Zuber J, Burk AC, Zeiser R, Sill H, Jayavelu AK, Zebisch A, Heuser M, Dengler MA, Jost PJ.
Sci Transl Med. 2025 Nov 26;17(826):eadu3313. Epub 2025 Nov 26.
82. Overall survival outcomes with first-line continuous ibrutinib and fixed-duration ibrutinib-venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age-matched European population. Ghia P, Ysebaert L, Janssens A, Stilgenbauer S, Fouad M, Schioppa CA, Hernández-Rivas JÁ, Tedeschi A.
Hemasphere. 2025 Oct 28;9(10):e70246.
81. Non-Hodgkin's lymphoma classification using 3D radiomics machine learning models for precision imaging in oncology. Lisson CG, Götz M, Wolf D, Manoj S, Gallee L, Schmidt SA, Tausch E, Schneider C, Stilgenbauer S, Beer AJ, Beer M, Sollmann N, Lisson CS.
BMC Med Imaging. 2025 Oct 30;25(1):435.
80. Tailoring intensive and less-intensive treatment in acute myeloid leukemia. Seeling C, Ganser A, Döhner H, Kühn MWM.
Semin Hematol. 2025 Jun;62(3):196-208. Epub 2025 Sep 13.
79. Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial. Hund I, Hess ME, Andrieux G, Stomper J, Greve G, Niemöller C, Ma T, Uhl D, Grishina O, Thol F, Heuser M, Bug G, Crysandt M, Neubauer A, Duyster J, Döhner H, Boerries M, Lübbert M, Becker H.
Leukemia. 2025 Nov;39(11):2816-2819. Epub 2025 Oct 7.
78. Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy. Krüger K, Gabdoulline R, Wichmann M, Schmidt BMW, Götze K, Braitsch K, Schmalbrock L, Bullinger L, Westendorf F, Fiedler W, Bergmann AK, Krauter J, Kaun S, Voß A, Koller E, Germing U, Wille K, Grießhammer M, Braess J, Föhring D, Reimer P, Kaiser U, Kirchen H, Hartmann F, Middeke JM, Röllig C, Döhner H, Döhner K, Beutel G, Thol FR, Heidel FH, Heuser M, Shahswar R.
Cancers (Basel). 2025 Sep 13;17(18):2993.
77. Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study. Visentin A, Gaffo E, Fürstenau M, Rogers KA, Panagiotis B, Cui C, Miller C, Haferlach C, Plevova K, Oscier D, Davis Z, Nguyen-Khac F, Roncaglia E, Rigolin GM, Athanasiadou A, Baran-Marszak F, Valiente A, Terol MJ, Abrisqueta P, Espinet B, Puiggros A, Martines A, Bonaldi L, Mauro FR, Scarfò L, Chatzikonstantinou T, Tausch E, Kreuzer KA, Kater A, Bosch F, Doubek M, Panagiotidis P, Kalashnikova O, Frezzato F, Calabretto G, Ruocco V, Orsi S, Cellini A, Angotzi F, Serafin A, Yi S, Eichhorst B, Woyach JA, Cuneo A, Ghia P, Stamatopoulos K, Trentin L, Bortoluzzi S.
Leukemia. 2025 Dec;39(12):2957-2967. Epub 2025 Sep 19.
76. CLL to Richter syndrome: Integrating network strategies with experiments elucidating disease drivers and personalized therapies. Maier J, Schwab JD, Werle SD, Marienfeld R, Stilgenbauer S, Möller P, Ikonomi N, Kestler HA.
Sci Adv. 2025 Sep 12;11(37):eadu7705. Epub 2025 Sep 12.
75. Development of a 29-Color Single-Tube Full Spectrum Flow Cytometry Assay for the Detection of Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia. Zhang Z, Wilhelm M, Sieber I, Döhner H, Feuring M.
Cytometry A. 2025 Sep;107(9):597-613. Epub 2025 Sep 12.
74. Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trial. Heilig CE, Heining C, Gnutzmann E, Roldan S, Heiligenthal L, Sparber-Sauer M, Hahn D, Dirksen U, Hamacher R, Flörcken A, Thorwarth A, Deinzer CKW, Gaidzik VI, Pfaff E, Hübschmann D, Arndt K, Pfister SM, Glimm H, Fröhling S, Schlenk RF.
Cancer Treat Res Commun. 2025;45:100986. Epub 2025 Sep 3.
73. Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial. Simon F, Ligtvoet R, Bohn JP, Nösslinger T, von Tresckow J, Liersch R, Gaska T, Jentsch-Ulrich K, Gärtner M, Wolff T, Schwaner I, Wolf D, Schneider C, Vehling-Kaiser U, Ritgen M, Spoer C, Eckart MJ, Decker T, Chakupurakal G, Schöttker B, Kisro J, Kreuzer KA, Tausch E, Stilgenbauer S, Robrecht S, Stumpf J, Fink A, Fürstenau M, Fischer K, Goede V, Hallek MJ, Eichhorst BF.
Blood. 2025 Dec 25;146(26):3153-3162.
72. Epidemiology, Real-World Treatment, and Economic Burden of Waldenström Macroglobulinemia: A Comprehensive Analysis Based on Anonymized Claims Data Between 2010 and 2022. Buske C, Herold M, Bahar N, Yang K, Tang B, Müller S, Hess G.
Value Health Reg Issues. 2025 Nov;50:101162. Epub 2025 Sep 5.
71. A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1mut AML in MRDneg remission after intensive induction. Döhner K, Döhner H, Späth D, Kapp-Schwoerer S, Gilkes A, Thomas I, Johnson S, Potter N, Bevan Y, Othman J, Russell NH, Röllig C, Thiede C, Bornhäuser M, Oellerich T, Hood T, Elder J, Carvajal LA, DiMartino J, Dillon R. Hemasphere. 2025 Aug 22;9(8):e70198. doi: 10.1002/hem3.70198. eCollection 2025 Aug.
70. The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL. Al-Sawaf O, Fürstenau M, Giza A, Robrecht S, von Tresckow J, Fink A, Simon F, Tausch E, Schneider C, Sivcheva L, Schwarer AP, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Juliusson G, da Cunha-Bang C, Illmer T, Gregor M, Thornton P, Janssens A, Tadmor T, Lindstrom V, Staber PB, Levin MD, Wendtner CM, Kreuzer KA, Ritgen M, Stilgenbauer S, Kater AP, Niemann CU, Fischer K, Eichhorst BF, Hallek MJ.
Blood. 2025 Nov 13;146(20):2406-2416.
69. Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial. Platzbecker U, Adès L, Montesinos P, Ammatuna E, Fenaux P, Baldus C, Bernardi M, Berthon C, Bocchia M, Bonmati C, Borlenghi E, Bornhäuser M, Carp D, Chantepie S, Crea E, Divona M, Döhner H, Ehninger G, Esteve Reyner J, Frayfer J, Garrido Diaz A, Gil C, Guarnera L, Hamm AF, Heiblig M, Heidenreich D, Krämer AJ, Ledoux MP, Lunghi M, Mancini V, Metzeler K, Miggiano MC, Müller-Tidow C, Peterlin P, Piciocchi A, Rieger K, Röllig C, Rossi G, Sanz MA, Serve H, Söhne M, Spiekermann K, Tavernier-Tardy E, Thiede C, Vives Polo S, Vogel W, Zappasodi P, Ziller-Walter P, Voso MT; SAL, AMCL-CG, AML-SG, OSHO, PETHEMA, HOVON and GIMEMA study groups.
J Clin Oncol. 2025 Oct 10;43(29):3160-3169. Epub 2025 Aug 18.
68. Treatment patterns of extracorporeal photopheresis in steroid-refractory graft versus host disease: A delphi study. Penack O, Bacigalupo A, Gavriilaki E, Greinix H, Malard F, Michonneau D, Olivieri A, Peric Z, Sala E, Solano C, Wolff D, Zeiser R.
Bone Marrow Transplant. 2025 Oct;60(10):1398-1401. Epub 2025 Jul 22.
67. Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML. Montesinos P, Marchione DM, Récher C, Heuser M, Vives S, Zarzycka E, Wang J, Riva M, Calado RT, Schuh AC, Yeh SP, Tron AE, Hui J, Gianolio DA, Choe S, Patel PA, De Botton S, DiNardo CD, Döhner H.
Blood Adv. 2025 Oct 28;9(20):5177-5189.
66. A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL. Guo M, Memis T, Ehrmann AS, Pittrof A, Baumann B, Ferrante F, Tausch E, Fischer K, Döhner H, Borggrefe T, Stilgenbauer S, Pannicke U, Schwarz K, Mertens D, Oswald F.
Blood. 2025 Oct 16;146(16):1936-1949.
65. Multi-Modal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification Across Disease States. Lachowiez CA, Asimomitis G, Bernard E, Devlin SM, Tazi Y, Creignou M, Germing U, Gattermann N, Gilkes A, Thomas I, Bullinger L, Döhner K, Malcovati L, Othman J, Dillon R, Eisfeld AK, Nicolet D, Issa GC, Daver N, Kadia TM, DiNardo CD, Ravandi F, Garcia-Manero G, Montalban-Bravo G, Russell N, Cazzola M, Döhner H, Huntly BJ, Hasserjian RP, Hellström-Lindberg E, Papaemmanuil E, Loghavi S.
Blood Cancer Discov. 2025 Sep 3;6(5):425-436.
64. Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice. Blombery P, Chatzikonstantinou T, Gerousi M, Rosenquist R, Gaidano G, Pospisilova S, Roberts AW, Birkinshaw RW, Rossi D, Scarfo L, Seymour JF, Stilgenbauer S, Wiestner A, Woyach JA, Brown JR, Ghia P, Stamatopoulos K; ERIC, the European Research Initiative on CLL.
Leukemia. 2025 Sep;39(9):2049-2060. Epub 2025 Jun 24.
63. Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance. Schmidt C, Scheubeck G, Jurinovic V, Sökler M, Forstpointner R, Buske C, Viardot A, Keller U, Graeven U, Marks R, Hänel M, Liersch R, Dürig J, Pott C, Hoster E, Unterhalt M, Hiddemann W.
Haematologica. 2025 Dec 1;110(12):3022-3031. Epub 2025 Jun 12.
62. Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generation tyrosine kinase inhibitor (TKI) treatment: Results of the prospective PONS trial. le Coutre P, Burchert A, Saußele S, Schwarzer T, Stintzing S, Pelzer U, Bullinger L, Elmaagacli A, Jehn C, Stegelmann F, Hochhaus A, Ernst T, Göthert JR.
Acta Haematol. 2025 May 5:1-13. doi: 10.1159/000545826. Online ahead of print. PMID: 40324350
61. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, Zucenka A, De Botton S, Grove CS, Mannis GN, Papayannidis C, Perl AE, Issa GC, Aldoss I, Bajel A, Dickens DS, Kühn MWM, Mantzaris I, Raffoux E, Traer E, Amitai I, Döhner H, Greco C, Kovacsovics TJ, McMahon CM, Montesinos P, Pigneux A, Shami PJ, Stone RM, Wolach O, Harpel JG, Chudnovsky Y, Yu L, Bagley RG, Smith AR, Blachly JS.
Blood. 2025 Aug 28;146(9):1065-1077.
60. Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma. Shumilov E, Scholz JK, Seib M, Mazzeo P, Wurm-Kuczera R, Vucinic V, Holtick U, Boyadzhiev H, Melchardt T, Hölscher AS, Schultze-Florey CR, Abdelhafez A, Velazquez GF, Ossami Saidy A, Lesan V, Schnetzke U, Kerkhoff A, Bacher U, Ghandili S, Aydilek E, Gebauer N, Weber T, Wulf GG, Glass B, Thurner L, Heidel FH, Schmid C, Viardot A, Hänel M, Dietrich S, Pabst T, Ayuk FA, von Tresckow B, Chapuy B, Pott C, Müller F, Lenz G.
Blood Adv. 2025 Aug 12;9(15):3955-3966.
59. Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study. Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, Bacher U, Staber PB, Mazzeo P, Leng C, Böckle D, Hölscher AS, Kauer J, Rotter N, Vucinic V, Rudzki JD, Nachbaur D, Bücklein VL, Schnetzke U, Krämer I, Wille K, Hasse A, von Tresckow B, Hänel M, Koenecke C, Velazquez GF, Viardot A, Schmid C, Thurner L, Wolf D, Subklewe M, Dreyling M, Dreger P, Dietrich S, Keller U, Jaeger U, Greil R, Pabst T, Lenz G, Chapuy B.
Blood Adv. 2025 Aug 12;9(15):3865-3877.
58. NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL. Ehrmann AS, Quijada-Álamo M, Close V, Guo M, Carracoi V, Pérez-Carretero C, Corchete LA, Friedrich T, Giaimo BD, Yosifov DY, Bloehdorn J, Rodríguez-Sánchez A, Tausch E, Schneider C, Döhner H, Kietzmann T, Borggrefe T, Stilgenbauer S, Oswald F, Hernández-Rivas JM, Mertens D.
Leukemia. 2025 Aug;39(8):1892-1904. Epub 2025 Jun 2.
57. Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial. Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Hellmuth JC, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Kamper P, Molin D, Jablonski J, Damaschin C, Robertz AS, Rosenbrock J, Fuchs M, Borchmann P, Behringer K.
Lancet Oncol. 2025 Aug;26(8):1081-1090. Epub 2025 Jul 10.
56. CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial. Teleanu MV, Heilig CE, Pirmann S, Hamacher R, Bauer S, Gaidzik VI, Mayer-Steinacker R, Al-Sabah J, Roldan Pinzon SSL, Süße H, Freitag A, Horak P, Kreutzfeldt S, Hutter B, Hüllein J, Sedlaczek O, Lehner B, Egerer G, Jäger D, Müller-Tidow C, Hübschmann D, von Kalle C, Barth TFE, Fröhling S, Schlenk RF.
ESMO Open. 2025 Jul;10(7):105498. Epub 2025 Jul 7.
55. Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. Wang M, Salek D, Belada D, Song Y, Jurczak W, Kahl BS, Paludo J, Chu MP, Kryachok I, Fogliatto L, Cheah CY, Morawska M, Sancho JM, Li Y, Patti C, Forsyth C, Zhang J, Lesley R, Ramadan S, Rule S, Dreyling M; Stephan Stilgenbauer as ECHO investigators; ECHO Investigators.
J Clin Oncol. 2025 Jul 10;43(20):2276-2284. Epub 2025 May 1.
54. Genotyping from targeted NGS data based on a small set of SNPs correctly matches patient samples. Yosifov DY, Schneider C, Stilgenbauer S, Mertens D, Tausch E.
BMC Res Notes. 2025 Jul 2;18(1):270.
53. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Daver N, Vyas P, Huls GA, Döhner H, Maury S, Novak J, Papayannidis C, Martinez Chamorro C, Montesinos P, Niroula R, Fenaux P, Esteve J, Wu SJ, De Voeght A, Mayer J, Valk PJM, Johnson L, Dong M, Liu K, Kuwahara SB, Caldwell K, Guru Murthy GS.
Blood. 2025 Jul 31;146(5):601-611.
52. International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC Recommendations. Kittai AS, Marchetti M, Al-Sawaf O, Benjamini O, Danilov AV, Davids MS, Eichhorst BF, Eyre TA, Frustaci AM, Hallek MJ, Hampel PJ, Herishanu Y, Hicks RJ, Kater AP, King RL, Martín-Subero JI, Owen C, Parry EM, Ponzoni M, Rossi D, Siddiqi T, Stilgenbauer S, Tam CS, Ten Hacken E, Thompson PA, Wierda WG, Gaidano G, Woyach JA, Ghia P.
Blood. 2025 Jul 17;146(3):291-303.
51. Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study. Roncaglia E, Gaffo E, Calabretto G, Fürstenau M, Rogers KA, Baliakas P, Cui C, Miller C, Haferlach C, Plevova K, Oscier D, Davis Z, Nguyen-Khac F, Rigolin GM, Athanasiadou A, Baran-Marszak F, Valiente A, Terol MJ, Abrisqueta P, Espinet B, Puiggros A, Martines A, Bonaldi L, Mauro FR, Scarfò L, Chatzikonstantinou T, Tausch E, Kreuzer KA, Kater A, Bosch F, Doubek M, Panagiotidis P, Kalashnikova O, Frezzato F, Ruocco V, Orsi S, Salek K, Merlo R, Caregari A, Glogovitis I, Cellini A, Angotzi F, Serafin A, Yi S, Eichhorst B, Woyach JA, Cuneo A, Ghia P, Stamatopoulos K, Trentin L, Visentin A, Bortoluzzi S.
J Hematol Oncol. 2025 Jul 22;18(1):74.
50. Enhancer hijacking discovery in acute myeloid leukemia by pyjacker identifies MNX1 activation via deletion 7q. Sollier E, Riedel A, Toprak UH, Wierzbinska JA, Weichenhan D, Schmid JP, Hakobyan M, Touzart A, Jahn E, Vick B, Brown-Burke F, Kelly K, Kelekci S, Pejkovska A, Goyal A, Bähr M, Breuer K, Chen MM, Llamazares-Prada M, Hartmann M, Schönung M, Correia N, Trumpp A, Abdullah Y, Klingmüller U, Mughal SS, Brors B, Westermann F, Ulrich E, Autry RJ, Schlesner M, Vosberg S, Herold T, Greif PA, Pfeifer D, Lübbert M, Fischer T, Heidel FH, Gebhard G, Walter W, Haferlach T, Eisfeld AK, Mrózek K, Nicolet D, Bullinger L, Smeenk L, Erpelinck-Verschueren C, Mulet-Lazaro R, Delwel R, Ernst A, Scherer M, Lutsik P, Jeremias I, Döhner K, Döhner H, Lipka DB, Plass C.
Blood Cancer Discov. 2025 Jul 1;6(4):343-363.
49. Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia. Mecklenbrauck R, Borchert N, Gabdoulline R, Poll P, Funke C, Brandes M, Dallmann LK, Fiedler W, Krauter J, Trummer A, Hertenstein B, Müller M, Lübbert M, Schwalenberg M, Voss A, Di Donato N, Bergmann A, Gaidzik V, Döhner K, Döhner H, Ganser A, Heidel FH, Thol FR, Heuser M.
Leukemia. 2025 Jul;39(7):1773-1777. Epub 2025 Apr 28.
48. Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. Lang F, Voss A, Kobbe G, Junghanss C, Beck J, Viardot A, Wendelin K, Panse J, Heberling L, Vucinic V, Böll B, Topp M, Hoelzer D, Serve H, Goekbuget N, Ottmann OG, Pfeifer H.
Leuk Lymphoma. 2025 Jun;66(6):1079-1087. Epub 2025 Feb 8.
47. Grüner, B. (2025). Echinokokkosen. Fuchs, André (Hrsg.), Rationelle Diagnostik und Therapie in der Inneren Medizin - Infektiologie., (S. 376). Urban & Fischer Verlag/Elsevier GmbH.
46. Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up. d'Amore F, Federico M, de Leval L, Ellin F, Hermine O, Kim WS, Lemonnier F, Vermaat JSP, Wulf G, Buske C, Dreyling M, Jerkeman M; ESMO and EHA Guidelines Committees.
Hemasphere. 2025 May 7;9(5):e70128. doi: 10.1002/hem3.70128. eCollection 2025 May.
45. GPR15LG binds CXCR4 and synergistically modulates CXCL12-induced cell signaling and migration. Albers DPJ, Novikova S, Vieyto-Nuñez J, Almeida-Hernández Y, Pastorio C, Klassen F, Weiss D, von Maltitz P, Jaikishan J, Datta M, Jumaa H, Jebaraj BMC, Stilgenbauer S, Kumar M, Maity PC, Buske C, Stifel U, Zinngrebe J, Fischer-Posovszky P, Chevigné A, Kirchhoff F, Sanchez-Garcia E, Münch J, Harms M.
Cell Commun Signal. 2025 May 20;23(1):234.
44. Prognostic Impact of COVID-19 Inflammation Score Response: A Sub-Group Analysis on Critically Ill Patients of the RuxCoFlam Trial. Weiss M, Hammersen J, Rudolphi S, Formann I, Träger K, Rücker FG, Grüner B, Allgöwer A, Birndt S, Fabisch C, Hochhaus A, Döhner K, Rosée P, Stegelmann F.
Life (Basel). 2025 May 14;15(5):781.
43. XPO1-dependency of DEK::NUP214 leukemia. Charles Cano F, Kloos A, Hebalkar RY, Plenge T, Geffers R, Kirchhoff H, Kattre N, Görlich K, Büsche G, Shcherbata HR, Scherr M, Döhner K, Gabdoulline R, Heuser M.
Leukemia. 2025 May;39(5):1102-1113. Epub 2025 Mar 27.
42. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. Sobas MA, Turki AT, Ramiro AV, Sánchez AH, Elicegui JM, González T, Melchor RA, Abáigar M, Tur L, Dall'Olio D, Sträng E, Tettero JM, Castellani G, Benner A, Döhner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Martínez-López J, Mills KI, Sierra J, Lehmann S, Porta MGD, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly BJP, Ossenkoppele G, Döhner H, Bullinger L.
Haematologica. 2025 May 1;110(5):1126-1140. Epub 2024 Nov 7.
41. Outcome of Patients with IDH-mutated AML following Allogeneic Stem Cell Transplantation - a Retrospective Analysis on behalf of the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, DRST. Schroeder T, Flossdorf S, Schuh C, Pabst C, Stadler M, Schetelig J, Wehr C, Stelljes M, Sala E, Burchert A, Winkler J, Reinhardt HC, Kröger N, Fleischhauer K, Rautenberg C.
Transplant Cell Ther. 2025 May;31(5):303.e1-303.e9. Epub 2025 Mar 7.
40. The significance of PAX5 in Merkel cell carcinoma. Chteinberg E, Kolarova J, Vogt J, Macamo A, Bormann F, Kretzmer H, Speel EJ, van den Oord J, Schneider C, Stilgenbauer S, Becker JC, Winnepenninckx V, Biessen E, Zenke M, Kurz AK, Siebert R, Zur Hausen A.
J Pathol. 2025 May;266(1):81-94. Epub 2025 Mar 4.
39. Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia. Goede V, Fischer K, Robrecht S, Giza A, Dyer MJ, Eckart MJ, Müller L, Smolej L, Kutsch N, Fink AM, Stilgenbauer S, Hallek MJ.
Blood Adv. 2025 May 27;9(10):2431-2435.
38. A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma. Frenking JH, Riedhammer C, Teipel R, Bassermann F, Besemer B, Bewarder M, Braune J, Brioli A, Brunner F, Dampmann M, Fenk R, Gezer DN, Goldman-Mazur S, Hanoun C, Högner M, Khandanpour C, Kolditz K, Kos I, Krönke J, Kull M, Landrin V, Leitner T, Merz M, von Metzler I, Michel CS, Müller-Tidow C, Theurich S, Trautmann-Grill K, Wäsch R, Zukovs R, Hänel M, Rasche L, Raab MS.
Hemasphere. 2025 Apr 17;9(4):e70114. doi: 10.1002/hem3.70114. eCollection 2025 Apr.
37. Correction: The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers. Roohani S, Handtke J, Hummedah K, Albertsmeier M, Andreou D, Apostolidis L, Augustin M, Bauer S, Billner M, Bösch F, Deinzer CKW, Deventer N, Duprée A, Eckert F, Engel L, Fechner K, Fritzsche H, Gaidzik V, Ghani S, Grützmann R, Guder WK, Hamacher R, Hecker JS, Hendricks A, Hillmann A, Houben P, Hübner G, Ivanyi P, Jentsch C, Jordan M, Kappl P, Kaths M, Kessler T, Kirchberg J, Knebel C, Krempien R, Lehner B, Lenze U, Lindner LH, Lörsch AM, Maguire N, Müller S, Piso P, Potkrajcic V, Reichardt P, Richter S, Schewe S, Schiffmann LM, Scholten F, Striefler JK, Schwarzbach M, Seidensaal K, Semrau S, Szkandera J, Szuszies CJ, Timmermann B, Tuchscherer A, Wiegering A, Winkelmann MT, Kaul D, Jakob J.
J Cancer Res Clin Oncol. 2025 Apr 24;151(4):149.
36. Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's Macroglobulinemia. Durot E, Abeykoon JP, Roos-Weil D, Kersten MJ, Kyriakou C, Moreno DF, Ansell SM, Auer R, Cao X, Owen RG, Yi S, Dogliotti I, Trneny M, Patterson CJ, Matous JV, Buske C, Treon SP, Advani R.
Semin Hematol. 2025 Apr;62(2):120-125. Epub 2025 Apr 8.
35. Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors. Castillo JJ, Autore F, Berinstein NL, Branagan AR, Dimopoulos MA, Fernandez de Larrea C, Ferrero S, Kapoor P, Kastritis E, Khwaja J, Minnema MC, Qiu L, Seymour JF, Vos JMI, Patterson CJ, Buske C, Matous JV, Treon SP, Palomba ML.
Semin Hematol. 2025 Apr;62(2):113-119. Epub 2025 Apr 8.
34. Report of Consensus Panel 4 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphoma. Tedeschi A, Auer R, Autore F, Castillo JJ, Gatt ME, Kimby E, Moreno DF, Owen RG, Qiu L, Roccaro AM, Sarosiek S, Sekiguchi N, Seymour JF, Varettoni M, Patterson CJ, Matous JV, Buske C, Treon SP, Sanz RG.
Semin Hematol. 2025 Apr;62(2):106-112. Epub 2025 Apr 8.
33. Report of Consensus Panel 3 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with high-risk disease. Kapoor P, Dimopoulos MA, Ansell SM, Kastritis E, Advani R, Durot E, Morel P, Kyriakou C, Hajek R, Drandi D, Abeykoon JP, Chow S, Cao X, Patterson CJ, Matous JV, Buske C, Treon SP, Kersten MJ.
Semin Hematol. 2025 Apr;62(2):90-105. Epub 2025 Apr 8.
32. Report of consensus panel 2 from the 12th international workshop on the management of Bing-Neel syndrome in patients with Waldenstrom's Macroglobulinemia. Sarosiek S, Becking AL, Branagan A, Ferrero S, Khwaja J, Kimby E, Roos-Weil D, Sekiguchi N, Trneny M, Yi S, Patterson CJ, Buske C, Matous JV, Treon SP, Minnema MC.
Semin Hematol. 2025 Apr;62(2):85-89. Epub 2025 Apr 16.
31. Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenström macroglobulinemia related neuropathy. D'Sa S, Khwaja J, Chow S, Dimopoulos MA, Dogliotti I, Gatt ME, Hajek R, Lindsay J, Merlini G, Morel P, Tedeschi A, Cerchione C, Leiba M, Patterson CJ, Treon SP, Buske C, Matous JV, Varettoni M, Vos JMI, Eftimov F, Lunn MP, Kastritis E.
Semin Hematol. 2025 Apr;62(2):76-84. Epub 2025 May 2.
30. Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia. Treon SP, Patterson CJ, Matous J, Buske C.
Semin Hematol. 2025 Apr;62(2):71-75. No abstract available.
29. Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patients. Rautenberg C, Middeke JM, Röllig C, Stelljes M, Gaidzik V, Kriege O, Verbeek M, Koch K, Unglaub JM, Thol F, Krause SW, Hänel M, Neuerburg C, Vucinic V, Jehn CF, Wass M, Heuser M, Fransecky L, Chemnitz J, Holtick U, Schäfer-Eckart K, Schröder J, Kraus S, Krüger W, Kaiser U, Scholl S, Kobbe G, Jäger PS, Alakel N, von Bonin M, Sockel K, Hanoun M, Platzbecker U, Holderried TAW, Morgner A, Sauer T, Götze KS, Wagner-Drouet E, Döhner K, Döhner H, Schliemann C, Schetelig J, Bornhäuser M, Germing U, Flossdorf S, Schroeder T, Stölzel F.
Blood Cancer J. 2025 Apr 8;15(1):60.
28. Subgrouping germinal center-derived B-cell lymphomas based on machine learning-deduced DNA methylation modules. Glaser S, Fischer A, Martínez-Manjón JE, López C, Kretzmer H, Burkhardt B, Hübschmann D, Hummel M, Klapper W, Kolarova J, Kreuz M, Ott G, Radlwimmer B, Rosolowski M, Schlesner M, Rosenwald A, Stilgenbauer S, Wagener R, Zwir I, Trümper L, Küppers R, Lichter P, Ammerpohl O, Del Val C, Siebert R; ICGC MMML-Seq consortium.
Leukemia. 2025 Apr;39(4):967-971. Epub 2025 Mar 10.
27. Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN). Manz K, Heidel FH, Koschmieder S, Schlag R, Lipke J, Stegelmann F, Griesshammer M, Klausmann M, Crodel C, Hochhaus A, Schulz H, Göthert JR, Al-Ali H, Becker H, Reiter A, Beutel G, Kricheldorf K, Brümmendorf TH, Hoffmann W, Döhner K, Isfort S; German Study Group for Myeloproliferative Neoplasms (GSG-MPN).
Leukemia. 2025 Apr;39(4):864-875. Epub 2025 Feb 25.
26. Intestinal perforation following allogeneic stem cell transplantation caused by Epstein-Barr virus-positive mucocutaneous ulcer. Hirschbühl K, Schaller T, Märkl B, Amerein A, Gebhard M, Braun G, Wasserberg S, Sala E, Trepel M, Schmid C.
Haematologica. 2025 Apr 1;110(4):1038-1040. Epub 2024 Dec 5.
25. Evaluation and management of hepatic dysfunction, portal hypertension and portal/splanchnic vein thrombosis in patients with myelofibrosis undergoing allogeneic haematopoietic cell transplantation: A practice based survey on behalf of the Chronic Malignancies Working Party of the EBMT. Battipaglia G, Polverelli N, Tuffnell J, Chiusolo P, Robin M, Gambella M, Broers A, Sala E, Passweg J, Furst S, Friis LS, Dulery R, de Witte M, Srour M, Finazzi MC, Wehr C, Nagler A, Richardson D, Bethge W, Clark A, Drozd-Sokolowska J, Raj K, Czerw T, Hernández-Boluda JC, McLornan DP.
Curr Res Transl Med. 2025 Jan-Mar;73(1):103476. Epub 2024 Oct 29.
24. Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistry. Cho HR, Isfort S, Kricheldorf K, Stegelmann F, Klausmann M, Heidel FH, Griesshammer M, Schulz H, Hochhaus A, Göthert J, Schlag R, Hollburg W, Teichmann L, Sockel K, Wilop S, Gezer D, Kirschner M, Döhner K, Brümmendorf TH, Koschmieder S; German Study Group for Myeloproliferative Neoplasms (GSG‐MPN).
Hemasphere. 2025 Mar 17;9(3):e70090. doi: 10.1002/hem3.70090. eCollection 2025 Mar.
23. Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia. Pullarkat V, Pratz KW, Döhner H, Recher C, Thirman MJ, DiNardo CD, Fenaux P, Schuh AC, Wei AH, Pigneux A, Jang JH, Juliusson G, Miyazaki Y, Selleslag D, Arellano ML, Liu C, Ridgeway JA, Potluri J, Schuler J, Konopleva M.
Blood Cancer J. 2025 Mar 28;15(1):49.
22. Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party. Duque-Afonso J, Finke J, Ngoya M, Galimard JE, Schetelig J, Eder M, Rösler W, Bug G, Neubauer A, Edinger M, Wulf GG, Jindra P, Einsele H, Stelljes M, Selleslag D, Wagner-Drouet EM, Bunjes D, Spyridonidis A, Brissot E, Nagler A, Ciceri F, Mohty M.
Bone Marrow Transplant. 2025 Mar;60(3):373-379. Epub 2024 Dec 19.
21. MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial. Fürstenau M, Robrecht S, Schneider C, Tausch E, Giza A, Ritgen M, Bittenbring JT, Hebart H, Schöttker B, Illert ALL, Graeven U, Stoltefuss A, Heinrich B, Eckert R, Fink AM, Stumpf J, Fischer K, Al-Sawaf O, Simon F, Kleinert F, Weiss J, Kreuzer KA, Schilhabel A, Brüggemann M, Langerbeins P, Stilgenbauer S, Eichhorst B, Hallek MJ, Cramer P.
Blood. 2025 Mar 20;145(12):1282-1292.
20. Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma. Grieb N, Oeser A, Ferle M, Hanke F, Flossdorf S, Sauer S, Goldschmidt H, Müller-Tidow C, Salwender HJ, Fenk R, Engelhardt M, Zeiser R, Vucinic V, Franke GN, Blau IW, Teschner D, Einsele H, Kimmich C, Kull M, Besemer B, Gagelmann N, Kröger N, Neumuth T, Platzbecker U, Merz M; German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST).
Bone Marrow Transplant. 2025 Mar;60(3):335-345. Epub 2024 Dec 5.
19. CXCR4 Inhibition Enhances the Efficacy of CD19 Monoclonal Antibody-Mediated Extermination of B-Cell Lymphoma. Khunti N, Kumar M, Datta M, Harelimana JD, Harms M, Albers D, Kirchhoff F, Münch J, Stenger S, Buske C, Maity PC.
Int J Mol Sci. 2025 Feb 26;26(5):2024.
18. Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial. Hoffmann S, Schrezenmeier E, Desmarets M, Halleck F, Durrbach A, Peters L, Tremmel AT, Seidel A, Führer M, Bachmann F, Schrezenmeier J, Greiner J, Körper S, Hofmann H, Ludwig C, Vieweg C, Jahrsdörfer B, Budde K, Schmidt M, Münch J, Joher N, Daguindau E, Grüner B, Brunotte G, Vauchy C, Seifried E, Bradshaw D, Estcourt LJ, Roberts DJ, Toussirot E, Rijnders B, Tiberghien P, Schrezenmeier H.
EBioMedicine. 2025 Feb 27;113:105613. Epub 2025 Feb 27.
17. Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. Heyman BM, Opat SS, Wahlin BE, Dimopoulos MC, Castillo JJ, Tedeschi A, Tam CS, Buske C, Owen RG, Leblond V, Trotman J, Barnes G, Chan WY, Schneider J, Allewelt H, Cohen A, Matous JV.
Blood Adv. 2025 Feb 25;9(4):722-728.
16. Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia. Tan YH, Yoon DH, Davies AJ, Buske C, Boo YL, Somasundaram N, Lim F, Ong SY, Jeyasekharan A, Izutsu K, Kim WS, Chan JY.
Discov Oncol. 2025 Feb 14;16(1):181.
15. Future perspectives of fertility protection. Bundschu K, Aleksandrova-Yankulovska S, Denzer C, Dornbrach T, Eberhart S, Glisic L, Barata AG, Gündel H, Hönig K, Janni W, Khinda K, Rafensteiner L, Siebert R, Steger F, Stilgenbauer S, Wabitsch M, Wiesmüller L, Wilhelm M, Wojak B, Hancke K.
J Reprod Immunol. 2025 Feb 12;168:104455. Epub 2025 Feb 12.
14. Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine. Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman UU, Crysandt M, Jost E, Thol F, Heuser M, Götze KS, Schlenk RF, Salih HR, Schittenhelm MM, Heil G, Schwaenen C, Müller-Tidow C, Brugger W, Kündgen A, de Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, May AM, Wäsch R, Duyster J, Döhner K, Ganser A, Döhner H, Hackanson B, Becker H, Lübbert M.
Eur J Haematol. 2025 Feb;114(2):231-237. Epub 2024 Oct 13.
13. Endpoint Surrogacy in First-Line Chronic Lymphocytic Leukemia. Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, Fürstenau M, Goede V, von Tresckow J, Langerbeins P, Fink AM, Huber H, Tausch E, Schneider C, Wendtner CM, Ritgen M, Dreyling M, Müller L, Jacobasch L, Heinz WJ, Vehling-Kaiser U, Sivcheva L, Böttcher S, Dreger P, Illmer T, Gregor M, Staber PB, Stilgenbauer S, Niemann CU, Kater AP, Fischer K, Eichhorst B, Hallek M, Al-Sawaf O.
J Clin Oncol. 2025 Feb;43(4):381-391. Epub 2024 Aug 23.
12. Peripheral Neuropathy in the Phase 3 ASPEN Study of Bruton Tyrosine Kinase Inhibitors for Waldenström Macroglobulinemia. Heyman BM, Opat SS, Wahlin BE, Dimopoulos MAA, Castillo JJ, Tedeschi A, Tam CS, Buske C, Owen RG, Leblond V, Trotman J, Barnes G, Chan WY, Schneider J, Allewelt H, Cohen AC, Matous JV.
Blood Adv. 2025 Feb 25;9(4):722-728.
11. Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial. Langerbeins P, Robrecht S, Nieper P, Cramer P, Fürstenau M, Al-Sawaf O, Simon F, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Schneider C, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Zahn MO, Dörfel S, Staib P, Behlendorf T, Hensel M, Hebart H, Klaproth H, Block A, Liersch R, Hauch U, Heinrich B, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M.
J Clin Oncol. 2025 Feb;43(4):392-402. Epub 2024 Nov 27.
10. Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL. Pavlova S, Malcikova J, Radova L, Bonfiglio S, Cowland JB, Brieghel C, Andersen MK, Karypidou M, Biderman B, Doubek M, Lazarian G, Rapado I, Vynck M, Porret NA, Andres M, Rosenberg D, Sahar D, Martínez-Laperche C, Buño I, Hindley A, Donaldson D, Sánchez JB, García-Marco JA, Serrano-Alcalá A, Ferrer-Lores B, Fernández-Rodriguez C, Bellosillo B, Stilgenbauer S, Tausch E, Nikdin H, Quinn F, Atkinson E, van de Corput L, Yildiz C, Bilbao-Sieyro C, Florido Y, Thiede C, Schuster C, Stoj A, Czekalska S, Chatzidimitriou A, Laidou S, Bidet A, Dussiau C, Nollet F, Piras G, Monne M, Smirnova S, Nikitin E, Sloma I, Claudel A, Largeaud L, Ysebaert L, Valk PJM, Christian A, Walewska R, Oscier D, Sebastião M, da Silva MG, Galieni P, Angelini M, Rossi D, Spina V, Matos S, Martins V, Stokłosa T, Pepek M, Baliakas P, Andreu R, Luna I, Kahre T, Murumets Ü, Pikousova T, Kurucova T, Laird S, Ward D, Alcoceba M, Balanzategui A, Scarfo L, Gandini F, Zapparoli E, Blanco A, Abrisqueta P, Rodríguez-Vicente AE, Benito R, Bravetti C, Davi F, Gameiro P, Martinez-Lopez J, Tazón-Vega B, Baran-Marszak F, Davis Z, Catherwood M, Sudarikov A, Rosenquist R, Niemann CU, Stamatopoulos K, Ghia P, Pospisilova S.
Hemasphere. 2025 Jan 20;9(1):e70065. doi: 10.1002/hem3.70065. eCollection 2025 Jan.
9. Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML. Cocciardi S, Saadati M, Weiß N, Späth D, Kapp-Schwoerer S, Schneider I, Meid A, Gaidzik VI, Skambraks S, Fiedler W, Kühn MWM, Germing U, Mayer KT, Lübbert M, Papaemmanuil E, Thol F, Heuser M, Ganser A, Bullinger L, Benner A, Döhner H, Döhner K.
Hemasphere. 2025 Jan 15;9(1):e70060. doi: 10.1002/hem3.70060. eCollection 2025 Jan.
8. Disease characteristics and outcomes of acute myeloid leukemia in germline RUNX1 deficiency (Familial Platelet Disorder with associated Myeloid Malignancy). Ernst MPT, Versluis J, Valk PJM, Bierings M, Tamminga RYJ, Hooimeijer LH, Döhner K, Gresele P, Tawana K, Langemeijer SMC, Van der Reijden BA, Podgornik H, Sever M, Tvedt THA, Vulliamy T, Fitzgibbon J, Dokal I, Baliakas P, Bastida JM, Pohlkamp C, Haferlach T, Larcher L, Soulier J, Schutgens REG, Freson K, Duployez N, Löwenberg B, Ericson K, Cammenga J, Ripperger T, Raaijmakers MHGP.
Hemasphere. 2025 Jan 16;9(1):e70057. doi: 10.1002/hem3.70057. eCollection 2025 Jan.
7. Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL. Arseni L, Sigismondo G, Yazdanparast H, Hermansen JU, Mack N, Ohl S, Kalter V, Iskar M, Kalxdorf M, Friedel D, Rettel M, Paul Y, Ringshausen I, Eldering E, Dubois J, Kater AP, Zapatka M, Roessner PM, Tausch E, Stilgenbauer S, Dietrich S, Savitski MM, Skånland SS, Krijgsveld J, Lichter P, Seiffert M.
Nat Commun. 2025 Jan 26;16(1):1041.
6. Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case report. Seeling C, Dahlum S, Marienfeld R, Jan V, Rack B, Gerstenmaier U, Beer AJ, Mayer-Steinacker R, Thaiss W, Barth TFE, Seufferlein T, Gaisa NT, Stilgenbauer S, Janni W, Siebert R, Döhner H, Gaidzik VI.
J Cancer Res Clin Oncol. 2025 Jan 16;151(1):37.
5. Correction: Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic. Arndt V, Doege D, Fröhling S, Albers P, Algül H, Bargou R, Bokemeyer C, Bornhäuser M, Brandts CH, Brossart P, Brucker SY, Brümmendorf TH, Döhner H, Gattermann N, Hallek M, Heinemann V, Keilholz U, Kindler T, von Levetzow C, Lordick F, Neumann UP, Peters C, Schadendorf D, Stilgenbauer S, Zander T, Zips D, Braun D, Seufferlein T, Nettekoven G, Baumann M.
J Cancer Res Clin Oncol. 2025 Jan 18;151(1):39.
4. Acute Effects of Slow-Paced Breathing on Measures of HRV in Hospitalized Patients With Bilateral COVID-19 Pneumonia: A Secondary Analysis of a Randomized Clinical Trial. Balint EM, Grüner B, Gündel H, Haase S, Kaw-Geppert M, Thayer J, Weimer K, Jarczok MN.
Psychosom Med. 2025 Jan 1;87(1):74-83.
3. The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers. Roohani S, Handtke J, Hummedah K, Albertsmeier M, Andreou D, Apostolidis L, Augustin M, Bauer S, Billner M, Bösch F, Deinzer CKW, Deventer N, Duprée A, Eckert F, Engel L, Fechner K, Fritzsche H, Gaidzik V, Ghani S, Grützmann R, Guder WK, Hamacher R, Hecker JS, Hendricks A, Hillmann A, Houben P, Hübner G, Ivanyi P, Jentsch C, Jordan M, Kappl P, Kaths M, Kessler T, Kirchberg J, Knebel C, Krempien R, Lehner B, Lenze U, Lindner LH, Lörsch AM, Maguire N, Müller S, Piso P, Potkrajcic V, Reichardt P, Richter S, Schewe S, Schiffmann LM, Scholten F, Striefler JK, Schwarzbach M, Seidensaal K, Semrau S, Szkandera J, Szuszies CJ, Timmermann B, Tuscherer A, Wiegering A, Winkelmann MT, Kaul D, Jakob J.
J Cancer Res Clin Oncol. 2025 Jan 4;151(1):30.
2. Radioimmunotherapy of acute myeloid leukemia: a critical assessment of its prospects and limitations. Bunjes D.
Expert Rev Hematol. 2025 Jan;18(1):81-89. Epub 2025 Jan 10.
1. Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project. Voso MT, Guarnera L, Lehmann S, Döhner K, Döhner H, Platzbecker U, Russell NH, Dillon RJ, Thomas I, Ossenkoppele GJ, Haferlach T, Vignetti M, La Sala E, Piciocchi A, Fazi P, Villaverde Ramiro Á, Tur Giménez L, Gurnari C, Bullinger L, Hernandez JM.
Blood. 2025 Jan 9;145(2):234-243.